Impact of acute otitis media clinical practice guidelines on antibiotic and analgesic prescriptions: a systematic review by Deniz, Y et al.
  1Deniz Y, et al. Arch Dis Child 2018;0:1–6. doi:10.1136/archdischild-2017-314103
Review
Impact of acute otitis media clinical practice 
guidelines on antibiotic and analgesic prescriptions:  
a systematic review
Yelin Deniz,1 Rick T van Uum,1 Marieke L A de Hoog,1 Anne G M Schilder,1,2 
Roger A M J Damoiseaux,1 Roderick P Venekamp1
To cite: Deniz Y, van Uum RT, 
de Hoog MLA, et al. 
Arch Dis Child Epub ahead of 
print: [please include Day 
Month Year]. doi:10.1136/
archdischild-2017-314103
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
archdischild- 2017- 314103).
1Julius Center for Health 
Sciences and Primary Care, 
University Medical Center 
Utrecht, Utrecht University, 
Utrecht, The Netherlands
2evidENT, Ear Institute, 
University College London, 
London, UK
Correspondence to
Rick T van Uum, Julius Center 
for Health Sciences and Primary 
Care, University Medical Center 
Utrecht, Utrecht University, 
Utrecht 3508 GA, The 
Netherlands;  
 R. T. vanUum- 2@ umcutrecht. nl
YD and RTU contributed equally.
Received 13 September 2017
Revised 24 January 2018
Accepted 25 January 2018
AbsTRACT
background Clinical practice guidelines focusing on 
judicious use of antibiotics for childhood acute otitis 
media (AOM) have been introduced in many countries 
around the world.
Objective To systematically review the effects of 
these guidelines on the prescription of antibiotics and 
analgesics for children with AOM.
Methods Systematic searches of PubMed, Embase and 
Cochrane Library from inception to 6 June 2017 using broad 
search terms. Studies specifically aimed at evaluating the 
effects of introduction of national AOM practice guidelines 
on type of antibiotic and/or analgesic prescriptions were 
included, irrespective of design, setting or language. The Risk 
Of Bias In Non-randomized Studies of Interventions tool was 
used to assess risk of bias.
Results Of 411 unique records retrieved, seven 
studies conducted in six different countries (France, 
Italy, Spain, Sweden, UK and USA (twice)) compared 
data before and after guideline introduction. All studies 
had an observational design, using longitudinal data of 
children aged under 15 years (n=200–4.6 million) from 
either routine care, insurance databases or electronic 
surveys. Risk of bias of all studies was judged serious 
to critical. Of the five studies reporting on antibiotic 
prescription rates, three showed a decline of 5%–12% 
up to 3 years after guideline introduction and two 
found no or negligible effect. In one US study, the 
initial 9% decline decreased to 5% after 4–6 years. 
The recommended first choice antibiotic was prescribed 
more frequently (9%–58% increase) after guideline 
introduction in four out of five studies reporting on this 
outcome. Analgesic prescription rates for AOM were 
reported in one US study and increased from 14% to 
24% after guideline introduction.
Conclusion Based upon what is published, the effects 
of introduction of national clinical practice guidelines 
on antibiotic and analgesic prescribing for children with 
AOM seem modest at the most.
Registration PROSPERO: CRD42016050976.
InTROduCTIOn
With emerging antimicrobial resistance posing a 
serious threat to global public health, promoting 
judicious use of antibiotics has become a top 
priority for governments worldwide. As a conse-
quence, clinical practice guidelines for common 
infectious diseases, including acute otitis media 
(AOM), have been introduced and updated in 
many countries over the past decades.1 Although 
AOM guidelines vary regarding specific recom-
mendations across countries, they generally 
emphasise the importance of accurate diagnosis 
and adequate analgesia as well as advocating selec-
tive antibiotic prescribing.1 
It has been suggested that guideline adherence 
for AOM may be suboptimal2 due to a variety of 
factors, such as fear of serious complications and 
parental pressure to prescribe antibiotics.3 In daily 
practice, antibiotics are commonly prescribed to 
children with AOM, ranging from around 50% 
in the Netherlands4 to 80% in the USA,5 whereas 
analgesics are only recommended in a minority of 
cases.6
However, the true impact of introducing AOM 
guidelines on prescription of antibiotics and analge-
sics for children with AOM in daily practice has not 
been reviewed systematically. We aim to do so and 
provide an overview of current available studies that 
compare prescription data before and after national 
AOM clinical practice guideline introduction.
MeThOds
search strategy and study selection
We performed systematic searches of the PubMed, 
Embase and Cochrane Library databases from 
inception to 6 June 2017 using database-specific 
syntaxes of keywords relevant to ‘acute otitis 
media’ and ‘guidelines’ (see online supplementary 
for full search strategies). After removing duplicates 
(RefWorks), two reviewers (YD and RTvU) inde-
pendently screened titles and abstracts for inclu-
sion. Discussion with a third and fourth reviewer 
(MLAdH and RPV) resolved any discrepancies. We 
screened reference lists of included studies for addi-
tional studies.
We included all original studies, irrespective of 
design, setting or language, evaluating the effects 
of the introduction of national clinical practice 
guidelines on prescription of antibiotics (rate and 
type) and/or analgesics for children (up to the age 
of 16 years) with AOM by comparing data before 
and after guideline introduction. We only included 
studies in which the time between data collection 
before and after guideline introduction was less 
than 5 years; this was to minimise the impact of 
other factors that may affect AOM epidemiology 
and subsequent prescription rates, for example, the 
introduction of pneumococcal conjugate vaccines 
and anti-smoking campaigns.
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data extraction and synthesis
The primary outcome of interest was the overall antibiotic 
prescription rate for AOM. Secondary outcomes included type 
of antibiotic prescribed and analgesic prescription rate.
Two review authors (YD and RTvU) independently extracted 
the following data from the included studies: characteristics of 
study (year, country, design, setting and data source), study popu-
lation (number and age of children with AOM), guideline details 
(date of introduction, method of dissemination and manage-
ment recommendations) and data on our predefined outcomes. 
Discussion with a third and fourth reviewer (MLAdH and RPV) 
resolved any discrepancies. To obtain further information on 
guideline dissemination strategies, we contacted authors of the 
original publications as well as clinical scientists involved in 
guideline development in countries subject to this review.
Methodological quality of the included studies was assessed 
by three reviewers independently (YD, RTvU and RPV) using 
‘The Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I) tool’,7 and any discrepancies were resolved by 
discussion.
Antibiotic prescription rates, type of antibiotic and analgesic 
prescription rates before and after introduction of the AOM 
clinical practice guideline were presented for each study individ-
ually. Where before and after guideline introduction data were 
reported for individual years or subgroups, (such as age), we 
aimed to calculate averages.
ResulTs
search results and study characteristics
Figure 1 shows the search results; 20 of the 411 unique records 
were considered potentially relevant. Of these, seven studies8–14 
were suitable for inclusion in this review. For detailed informa-
tion of the included studies (see table 1); the seven studies were 
conducted in six countries: France, Italy, Spain, Sweden, UK and 
USA (two studies). All were observational studies using longitu-
dinal data of children aged under 15 years; they differed substan-
tially in terms of setting (primary vs secondary care), number of 
patients (n=200–4.6 million), study duration (6 months–10 years 
longitudinal data) and data source (routine care, insurance data-
bases or electronic surveys).
Table 2 summarises the key guideline recommendations of 
the included studies. Detailed information on guideline dissem-
ination strategies was obtained for Italy, Sweden, UK and USA 
(table 3). The method of dissemination varied considerably 
Figure 1 Flow chart.
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across countries, ranging from passive dissemination through 
online publication or paper copies targeted at individual physi-
cians only to extensive (public) media attention, interactive 
workshops and joint antibiotic stewardship campaigns.
Risk of bias assessment and study findings
Risk of bias was judged serious in six studies and critical in one; 
see figure 2. The primary and secondary outcome data are illus-
trated in figures 3 and 4. Two of the five studies reporting anti-
biotic prescription rates before and after guideline introduction 
showed no or a negligible effect. Three studies showed a decline 
of 5%–12% up to 3 years after guideline introduction.
One US study reported both the short- and long-term impact 
of guideline introduction; the decline of 9% in the first 3 years 
decreased to 5% after four to 6 years.
In four out of five studies reporting on the type of antibiotic 
prescribed, prescription of the recommended first choice antibi-
otic, either amoxicillin or penicillin V, increased by 9%–58% after 
guideline introduction, with inverse trends for amoxicillin/clavu-
lanic acid which decreased by 7%–36%.
Only one US study reported on analgesic prescription 
rates; this increased from 14% before to 24% after guideline 
introduction.
dIsCussIOn
The introduction of national AOM clinical practice guide-
lines seems to have at best a modest impact on antibiotic and 
analgesic prescribing; antibiotic prescription rates decrease 
by a maximum of 12% and analgesic rates increase by 10%. 
Its effect on the type of antibiotic is more substantial with 
an increase of up to 58% for the recommended first choice 
antibiotic.
In line with available literature,15 16 results from the study of 
Tyrstrup et al14 suggest that tailored guideline dissemination 
may have a larger impact on antibiotic prescription rates than 
passive dissemination only. Our findings also indicate that 
physicians find it easier to substitute rather than refrain from 
antibiotic prescribing. Reasons include their concerns about 
the risk of the child falling seriously ill when not prescribing 
antibiotics, or missing a diagnosis which would have been 
adequately treated with antibiotics.17 This is especially the 
case when dealing with young children, or in consultations 
in which physicians perceive parental pressure to prescribe 
antibiotics.17 Apparently, many physicians are either not 
convinced of, or unfamiliar with, the literature that refutes the 
risks of restrictive prescribing18 and parental expectations of 
antibiotics.3 17 19
Table 2 Guideline recommendations in included studies
study Id Country Year Condition Guideline recommendation (summary)
Tyrstrup et al14 Sweden 2010 Children 1–12 years with uncomplicated AOM First line Wait-and-see for 3 days
Second line Penicillin V (first choice antibiotic) 
Palma et al11 Italy 2010 Children >2 years with uncomplicated,
non-severe AOM
First line Analgesics, wait-and-see for 3 days
Second line First choice: high-dose amoxicillin (80–90 mg per kg per day)
Second choice: cephalosporin
Children 6 months–2 years with uncomplicated 
AOM Children >2 years with severe AOM*
First line First choice: high-dose amoxicillin (80–90 mg per kg per day)
Second choice: cephalosporin
Levy et al9 France 2011 Children >2 years with uncomplicated AOM First line Wait-and-see, reassessment after 48–72 hours
Second line High-dose amoxicillin (80–90 mg per kg per day)
Children <2 years with uncomplicated AOM
Children >2 years with severe AOM*
First line High-dose amoxicillin (80–90 mg per kg per day)
Second line Amoxicillin/clavulanic-acid or cefpodoxime in case of 
treatment failure
McGrath et al10 USA 2004 Children >2 years with uncomplicated,
non-severe AOM
First line Analgesics, wait-and-see for 3 days
Second line First choice: high-dose amoxicillin (80–90 mg per kg per day)
Second choice: cephalosporin
Children 6 months–2 years with uncomplicated 
AOM Children >2 years with severe AOM*
First line First choice: high-dose amoxicillin (80–90 mg per kg per day)
Second choice: cephalosporin
Coco et al8 USA 2004 Children >2 years with uncomplicated,
non-severe AOM
First line Analgesics, wait-and-see for 3 days
Second line First choice: high-dose amoxicillin (80–90 mg per kg per day)
Second choice: cephalosporin
Children 6 months–2 years with uncomplicated 
AOM Children >2 years with severe AOM*
First line First choice: high-dose amoxicillin (80–90 mg per kg per day)
Second choice: cephalosporin
Thompson et al13 UK 2003
2004
Children >2 years with uncomplicated,
non-severe AOM
First line Analgesics, wait-and-see for 24–72 hours
Second line Amoxicillin thrice daily 125–250 mg, for 5 days
Second choice: erythromycin, azithromycin or clarithromycin
Children <2 years or severe AOM or recurrent 
infections
First line Amoxicillin thrice daily 125–250 mg, for 5 days
Rios, et al12 Spain 2001 Children >6 months with uncomplicated AOM First line High-dose amoxicillin for a minimum of 5 days
Second line Amoxicillin/clavulanic-acid or ceftriaxone if no response 
within 48–72 hours
Children <6 months with uncomplicated AOM
Children >6 months with severe AOM
First line Amoxicillin/clavulanic-acid or ceftriaxone
Second line Tympanocentesis and treatment according to results of Gram 
staining and antibiotic sensitivity
*Severe AOM is defined as moderate to severe otalgia with fever >39°C.
AOM, acute otitis media; N/A, not available.
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Our findings should be interpreted with some caution. 
Despite our efforts to minimise the impact of external factors 
affecting childhood AOM epidemiology and prescribing 
patterns, such as anti-smoking campaigns, pneumococcal 
conjugate vaccination and strategies to promote breast-
feeding,20 21 we cannot rule out this has influenced our 
results. Also, we were not able to account for ongoing 
prescribing trends prior to the introduction of the guideline; 
none of the studies applied interrupted time-series analysis.22 
Importantly, dissemination of the guideline to the general 
audience suggesting that parents can manage milder cases of 
AOM themselves can lead to fewer overall AOM consulta-
tions and subsequent antibiotic prescriptions.23 Nevertheless, 
only two out of the seven studies reported on annual fluctua-
tions in AOM consultation rates and none of them accounted 
for this in their analyses.13 14 Besides, when parents do 
self-manage these milder cases of AOM, physicians may be 
faced with more severe AOM and thus prescribe antibiotics 
more frequently (leading to a relative increase over time). 
These aforementioned trends are not captured in the studies. 
Neither are the phenomena that, with explicit diagnostic 
guidance, physicians may diagnose AOM more accurately, 
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Figure 2 Risk of bias assessment.
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leading to fewer overall diagnoses and antibiotic prescrip-
tions, but at the same time a higher prescription rate per 
diagnosis.
Finally, the vast majority of analgesics for AOM are obtained 
over-the-counter rather than prescribed. This implies that our 
results regarding analgesic prescriptions for AOM are incom-
plete and preclude strong conclusions.
COnClusIOn
Based on what is published, the introduction of national AOM 
clinical practice guidelines seems to have at best a modest 
impact on antibiotics and analgesics prescription rates for 
childhood AOM. Future studies evaluating the impact of clin-
ical guidelines using longitudinal observational data should 
use a quasi-experimental approach, and take fluctuations in 
AOM consultation rates into account, to provide more mean-
ingful estimates on the impact on antibiotic and analgesic 
prescribing.
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